Literature DB >> 28349214

Diabetes in a child on growth hormone therapy: Answers.

Melanie Aldridge1, Tony Huynh2,3, Jose Prado3,4, Steven J McTaggart5,6.   

Abstract

Entities:  

Keywords:  Chronic kidney disease; Diabetes; Growth hormone; MODY

Mesh：

Substances：

Year:  2017        PMID： 28349214     DOI： 10.1007/s00467-017-3651-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  13 in total

1.  Severe hyperglycemia after renal transplantation in a pediatric patient with a mutation of the hepatocyte nuclear factor-1beta gene.

Authors:  Simon C Waller; Lesley Rees; Adrian S Woolf; Sian Ellard; Ewan R Pearson; Andrew T Hattersley; Coralie Bingham
Journal:  Am J Kidney Dis       Date:  2002-12       Impact factor: 8.860

Review 2.  Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.

Authors:  David R Clemmons
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

Review 3.  Recombinant human insulin-like growth factor I (rhIGF-I) and rhIGF-I/rhIGF-binding-protein-3: new growth treatment options?

Authors:  Arlan L Rosenbloom
Journal:  J Pediatr       Date:  2007-01       Impact factor: 4.406

Review 4.  Reviewing the safety of GH replacement therapy in adults.

Authors:  Kirstine Stochholm; Gudmundur Johannsson
Journal:  Growth Horm IGF Res       Date:  2015-06-19       Impact factor: 2.372

5.  Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment.

Authors:  W S Cutfield; P Wilton; H Bennmarker; K Albertsson-Wikland; P Chatelain; M B Ranke; D A Price
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

6.  HNF1B mutations associate with hypomagnesemia and renal magnesium wasting.

Authors:  Shazia Adalat; Adrian S Woolf; Karen A Johnstone; Andrea Wirsing; Lorna W Harries; David A Long; Raoul C Hennekam; Sarah E Ledermann; Lesley Rees; William van't Hoff; Stephen D Marks; Richard S Trompeter; Kjell Tullus; Paul J Winyard; Janette Cansick; Imran Mushtaq; Harjeeta K Dhillon; Coralie Bingham; Emma L Edghill; Rukshana Shroff; Horia Stanescu; Gerhart U Ryffel; Sian Ellard; Detlef Bockenhauer
Journal:  J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 10.121

7.  Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease.

Authors:  Richard N Fine; Martin Ho; Amir Tejani; Sandra Blethen
Journal:  J Pediatr       Date:  2003-05       Impact factor: 4.406

8.  Molecular and biochemical analysis of the MODY syndromes.

Authors:  W E Winter
Journal:  Pediatr Diabetes       Date:  2000-06       Impact factor: 4.866

9.  Clinical spectrum associated with hepatocyte nuclear factor-1beta mutations.

Authors:  Christine Bellanné-Chantelot; Dominique Chauveau; Jean-François Gautier; Danièle Dubois-Laforgue; Séverine Clauin; Sandrine Beaufils; Jean-Marie Wilhelm; Christian Boitard; Laure-Hélène Noël; Gilberto Velho; José Timsit
Journal:  Ann Intern Med       Date:  2004-04-06       Impact factor: 25.391

10.  Mutations in 12 known dominant disease-causing genes clarify many congenital anomalies of the kidney and urinary tract.

Authors:  Daw-Yang Hwang; Gabriel C Dworschak; Stefan Kohl; Pawaree Saisawat; Asaf Vivante; Alina C Hilger; Heiko M Reutter; Neveen A Soliman; Radovan Bogdanovic; Elijah O Kehinde; Velibor Tasic; Friedhelm Hildebrandt
Journal:  Kidney Int       Date:  2014-01-15       Impact factor: 10.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.